Follow The Filings

CATX Perspective Therapeutics

Perspective Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CATX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CATX insider trades
  • $42K bought by 2 insiders
  • $1.6M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Lantheus Alpha Therapy, LLC 10% owner, +1 joint filer
    Sale
    $777K 247,932 shares at $3.13 2.2% of stake
    Traded Sep 3–4 Filed Sep 8
  2. Lantheus Alpha Therapy, LLC 10% owner, +1 joint filer
    Sale
    $131K 42,129 shares at $3.11 0.4% of stake
    Traded Sep 2 Filed Sep 4
  3. Lantheus Alpha Therapy, LLC 10% owner
    Sale
    $357K 113,914 shares at $3.14 1% of stake
    Traded Aug 31–Sep 1 Filed Sep 4
  4. Lantheus Holdings, Inc. 10% owner
    Sale
    $112K 35,769 shares at $3.12 0.3% of stake
    Traded Sep 1 Filed Sep 3
  5. Lantheus Holdings, Inc. 10% owner
    Sale
    $246K 78,145 shares at $3.14 0.7% of stake
    Traded Aug 31 Filed Sep 2
  6. Jonathan Robert Hunt Chief Accounting Officer
    Buy
    $22K 11,000 shares at $2.03 +23% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
  7. Robert F Williamson III Director
    Buy
    $20K 9,498 shares at $2.10 +2595% to stake
    Traded Nov 12, 2025 Filed Nov 14, 2025

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13D/A —
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13D/A —
SCHEDULE 13G/A —
8-K 2.02,8.01,9.01
10-Q
SCHEDULE 13G —
8-K 8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
8-K 8.01,9.01
SCHEDULE 13G —
8-K 8.01,9.01
8-K 5.07
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,8.01,9.01
10-Q
8-K 2.02,8.01,9.01
SCHEDULE 13G/A —
8-K 8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.